New drug shows promise for Long-Term control of rare muscle disease
NCT ID NCT05332210
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the long-term safety of a drug called HBM9161 for people with generalized myasthenia gravis, a condition that causes muscle weakness. It involved 111 patients who had already completed a previous phase 3 study. The goal was to see if the drug is safe to use over a longer period when combined with their usual treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking daily life unlock myasthenia gravis mysteries?
- Can engineered immune cells tame a debilitating autoimmune disease?
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can DNA reveal the roots of a rare muscle disease?
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Could a new drug help keep myasthenia gravis symptoms at bay?